Unexpected Variations in Sites of Lithiation of N-(2-Methoxybenzyl)-pivalamide
作者:Keith Smith、Gamal El-Hiti、Amany Hegazy
DOI:10.1055/s-0029-1217722
日期:2009.9
Directed lithiation of N-(2-methoxybenzyl)pivalamide with two mole equivalents of t-BuLi in anhydrous THF at -78 ˚C followed by reactions with various electrophiles gave ring substitution, but ortho to the methoxy group rather than ortho to the pivaloylaminomethyl group, which was unexpected in view of earlier results reported with n-BuLi.
Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors
申请人:Pastor Fernández Joaquin
公开号:US20130029967A1
公开(公告)日:2013-01-31
There is provided compounds of formula (I), wherein A
1
, A
2
, A
3
, A
4
, n, the dotted lines, B
1
, B
1a
, B
2
, B
2a
, B
3
, B
3a
, B
4
, B
4a
, R
2
and R
3
have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.
A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).